All News
Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease
There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.
Read Article
Early RA pts given steroids (GC) do Not have short or long term benefits from GCs. 180 ERA pts given compared to 294 who did not. 5 yr F/U showed no differences in DAS28-CRP, HAQ or pain between groups. Steroids were used more in seronegative RA. https://t.co/CDUKDgsLRa
Links:
Dr. John Cush RheumNow ( View Tweet)
Using both glucocorticoids & PPI leads to additive risk of osteoporotic fractures - UK database studiedd 12351 RA pts - 1411 w/ OP Fx. Concomitant GCs + PPIs assoc w/ 1.6-fold risk of OP Fx (adj HR: 1.60) vs nonuse; more than 1.2-fold risk w/ either alone https://t.co/vvA6P5LEgs
Links:
Dr. John Cush RheumNow ( View Tweet)
We just started our last faculty panel on RA with audience Q&A.
#RNL2021 https://t.co/o1s2asdLcS
Dr. John Cush RheumNow ( View Tweet)
Mavrilimumab (anti-GM-CSF) metanalysis shows gret benefit in #RA - 1145 pts, 3 trials shows significant 12 week responses by: 1) DAS28-CRP remission (RR = 3.31); 2) ACR20 (RR = 2.38); 3) ACR50 (RR = 2.93) & 4) ACR70 (RR = 4.9). Where is it? https://t.co/9L5PFEB1DI
Links:
Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis faculty panel with audience Q&A #RNL2021 https://t.co/iSosAtHLCZ
Dr. John Cush RheumNow ( View Tweet)
Follow the hashtag #RNL2021 for all RheumNow Live coverage today!
Dr. John Cush RheumNow ( View Tweet)
Dr. Artie Kavanaugh leading the spondyloarthritis pod focusing on enthesitis and dactylitis management. #RNL2021 https://t.co/NCUwabTXVd
Dr. John Cush RheumNow ( View Tweet)
Join me at the @RheumNow SpA session happening now! #rheumatology #spondyloarthritis #ankylosing https://t.co/CTLq0xWQys
Nigil Haroon MD, PhD 💎🦜🌎🩺🔬 NigilHaroon ( View Tweet)
Leading the Rheumatoid Arthritis pod with discussions on pneumonia and RA and interstitial lung disease in RA. #RNL2021 https://t.co/psxMTHsOva
Dr. John Cush RheumNow ( View Tweet)
New podcast available! Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.
https://t.co/rPnLp2NfRq https://t.co/TSTP2tWxXy
Links:
Dr. John Cush RheumNow ( View Tweet)
Our in-person participants engaging with the psoriatic panel #RNL2021 https://t.co/N0Cdos3Rhb
Dr. John Cush RheumNow ( View Tweet)
News Feature: Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures
https://t.co/KazNPRXKNx https://t.co/pykBdbexzF
Links:
Dr. John Cush RheumNow ( View Tweet)
@RheumNow #RNL2021 Dr. Buttgereit on steroids in RA:
2.5 mg/d of prednisone increase total steroid amount in the body by 100% - great therapeutic effect but comes w/plethora of side effects.
Q: how do you feel out long term low dose steroids for RA?
Olga Petryna DrPetryna ( View Tweet)
Follow the hashtag #RNL2021 for all RheumNow Live coverage today and tomorrow!
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live has started! #RNL2021 https://t.co/CrNqnnKqUy
Dr. John Cush RheumNow ( View Tweet)
Metanalysis reveals significant heterogeneity in defining Refractory Disease in RA and polyarticular JIA. Should include: 1) Resistance to multiple drugs w/ different MOAs (≥2bDMARDs) and 2) Persistent symptoms and disease activity https://t.co/CL6Mr3cs7J
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: Are You a Super Rheum?
https://t.co/LsGpFNXlkp https://t.co/Q9iojEQNqL
Links:
Dr. John Cush RheumNow ( View Tweet)
Top 4 arthritis types that significantly increase the risk of CVA: 1) RA (RR=1.38), 2) ankylosing spondylitis (RR=1.49), 3) psoriatic arthritis (RR=1.33) & gout (RR=1.4). With these, the risk was higher in younger (<45 yrs) (RR = 1.46), not older (>65) https://t.co/Snb6OrtZJH
Links:
Dr. John Cush RheumNow ( View Tweet)
NAFLD, NASH and Risks with DMARDs and MTX
https://t.co/LYV9WycEjz https://t.co/Vx0jvhjCsd
Links:
Dr. John Cush RheumNow ( View Tweet)
